1 |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
|
2 |
Mao L, Li X, Gong S, et al. Serum exosomes contain ECRG4 mRNA that suppresses tumor growth via inhibition of genes involved in inflammation, cell proliferation, and angiogenesis[J]. Cancer Gene Ther, 2018, 25(9/10): 248-259.
|
3 |
Mashouri L, Yousefi H, Aref AR, et al. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance[J]. Mol Cancer, 2019, 18(1): 75.
|
4 |
Tai YL, Chen KC, Hsieh JT, et al. Exosomes in cancer development and clinical applications[J]. Cancer Sci, 2018, 109(8): 2364-2374.
|
5 |
XT, XR. Targeted therapeutic delivery using engineered exosomes and its applications in cardiovascular diseases[J]. Gene, 2016, 575(2Pt 2): 377-384.
|
6 |
Toffoli G, Hadla M, Corona G, et al. Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin[J]. Nanomedicine (Lond), 2015, 10(19): 2963-2971.
|
7 |
Xie C, Du LY, Guo FY, et al. Exosomes derived from microRNA-101-3p-overexpressing human bone marrow mesenchymal stem cells suppress oral cancer cell proliferation, invasion, and migration[J]. Mol Cell Biochem, 2019, 458(1/2): 11-26.
|
8 |
Hua L, Zhu GR, Wei JG. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy[J]. Cell Biol Int, 2018, 42(9): 1240-1249.
|
9 |
Han C, Zhou YB, An Q, et al. MicroRNA-1 (miR-1) inhibits gastric cancer cell proliferation and migration by targeting MET[J]. Tumour Biol, 2015, 36(9): 6715-6723.
|
10 |
Liu WZ, Li MK, Chen XM, et al. MicroRNA-1 suppresses proliferation, migration and invasion by targeting Notch2 in esophageal squamous cell carcinoma[J]. Sci Rep, 2018, 8(1): 5183.
|
11 |
Hudson RS, Yi M, Esposito D, et al. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer[J]. Nucleic Acids Res, 2012, 40(8): 3689-3703.
|
12 |
Wang ZS, Wang JL, Chen ZH, et al. MicroRNA-1-3p inhibits the proliferation and migration of oral squamous cell carcinoma cells by targeting DKK1[J]. Biochimie Et Biol Cell, 2018, 96(3): 355-364.
|
13 |
Haney MJ, Klyachko NL, Zhao YL, et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy[J]. J Control Release, 2015, 207: 18-30.
|
14 |
Alvarez-Erviti L, Seow Y, Yin HF, et al. Delivery of si RNA to the mouse brain by systemic injection of targeted exosomes[J]. Nat Biotechnol, 2011, 29(4): 341-345.
|
15 |
Haney MJ, Klyachko NL, Harrison EB, et al. TPP1 delivery to lysosomes with extracellular vesicles and their enhanced brain distribution in the animal model of batten disease[J]. Adv Healthc Mater, 2019, 8(11): e1801271.
|
16 |
Hadla M, Palazzolo S, Corona G, et al. Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models[J]. Nanomedicine (Lond), 2016, 11(18): 2431-2441.
|
17 |
Naseri Z, Oskuee RK, Jaafari MR, et al. Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo[J]. Int J Nanomedicine, 2018, 13: 7727-7747.
|
18 |
Gao S, Zhao ZY, Wu R, et al. miR-1 inhibits prostate cancer PC3 cells proliferation through the Akt/mTOR signaling pathway by binding to c-Met[J]. Biomedecine Pharmacother, 2019, 109: 1406-1410.
|
19 |
Jiao DM, Chen J, Li Y, et al. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT[J]. J Cell Mol Med, 2018, 22(7): 3526-3536.
|
20 |
Reid JF, Sokolova V, Zoni E, et al. miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation[J]. Mol Cancer Res, 2012, 10(4): 504-515.
|